^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AryoTrust (trastuzumab biosimilar)

    i
    Other names: TA4415V
    Company:
    AryoGen Pharmed, Inno Bio
    Drug class:
    HER2 inhibitor
    Related drugs:
    over1year
    Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance. (PubMed, Expert Opin Drug Saf)
    The results demonstrate that this trastuzumab biosimilar is a generally well-tolerated and safe treatment for HER2-positive BC. www.clinicaltrials.gov identifier is NCT06021379.
    P4 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    AryoTrust (trastuzumab biosimilar)
    over2years
    AryoTrust® (Trastuzumab) Safety Study (clinicaltrials.gov)
    P=N/A, N=597, Completed, AryoGen Pharmed Co.
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • AryoTrust (trastuzumab biosimilar)
    over5years
    Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer (clinicaltrials.gov)
    P3, N=108, Completed, AryoGen Pharmed Co. | Recruiting --> Completed
    Clinical • Trial completion • Head-to-Head
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    docetaxel • doxorubicin hydrochloride • AryoTrust (trastuzumab biosimilar) • cyclophosphamide intravenous